Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

Adjuvant systemic therapy was associated with improved rates of overall survival among patients who underwent surgical resection for MM.

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...

Hepatocellular carcinoma (HCC) management is rapidly evolving as systemic therapies and locoregional treatments are increasingly combined across disease ...

A University of Kentucky Markey Cancer Center study shows that a targeted form of radiation therapy can be safely delivered ...

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of ...

Please provide your email address to receive an email when new articles are posted on . One specialist highlighted cases in which systemic treatments, such as corticosteroids, are better. Another ...

You may understand what’s happening in your relationship, yet still feel stuck in the same patterns of conflict, shutdown, or distance. Many couples and individuals come to therapy feeling emotionally ...